Tweet
<img alt="" height="1" width="1" />
Novartis drug helps rare tumors, filing this year
Reuters
MILAN (Reuters) - Patients with advanced neuroendocrine tumors, a rare type of cancer, lived 5.1 months longer without their disease worsening when given Novartis's drug Afinitor, researchers said on Monday. ...
Novartis's Afinitor Fails to Slow Rare Form of Pancreatic Cancer in TrialBloomberg
Novartis To File Afinitor After Phase III Study DataWall Street Journal
Novartis International AG: Phase III Novartis data show potential benefit of ...Reuters (press release)
Frontier India - News, Analysis, Opinion
all 34 news articles »
More...